001-MCS-40-106_RD-03 (20.0) / Saved on: 20 Apr 2021
Protocol
 
Document Number: c39406431-[ADDRESS_313723] No.
EU Study No.N/A
BI Study No. 1490-[ADDRESS_313724](s)
TitleA multi-center, longitudinal 12-week pi[INVESTIGATOR_258210], utilizing a next generation cough monitor, in participants with idiopathic pulmonary fibrosis (IPF) or Non IPF Pulmonary Fibrosis
Lay TitleA study in people with pulmonary fibrosis to monitor cough with 
a wearable device
Clinical Phase N/A
Clinical Trial LeaderOn behalf of 
Phone / Fax: 
Email:
Coordinating Investigator
[CONTACT_7626]:
Email:
Current Version and DateVersion 1.0 / 16 Sep 2022  
Original Protocol 
Date16 Sep 2022 Page 1 of 71
Proprietary confidential information.
!!2022 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permissi on.
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 2 of 71
Proprietary confidential information © [ADDRESS_313725]-03 (20.0) / Saved on: 20 Apr 2021PROTOCOL SYNOPSIS
Company nameBoehringer Ingelheim 
Original Protocol date 16 Sep 2022
Revision date N/A
BI study number 1490-[ADDRESS_313726], utilizing next generation cough monitoring, in participants with idiopathic pulmonary fibrosis (IPF) or Non IPF pulmonary fibrosis. 
Coordinating 
Investigator
[INVESTIGATOR_258211](s) Multi-centre study in approximately 5-7 countries. 
Clinical phase N/A
Study rationale A further understanding of the similarities and differences in cough 
among persons with Non IPF forms of pulmonary fibrosis and IPF,together with insight into the pattern and impact of cough in these patients is required. The current pi[INVESTIGATOR_258212], indirect measures of cough intensity and the association between objective cough measures and lung physiology and various patient-reported outcome measures in a patient cohort with Non IPF forms of pulmonary fibrosis and IPF. 
Study objective(s) The primary objective of this study is to objectively quantify coughfrequency over 12 weeks in a cohort of subjects with IPF or Non IPF pulmonary fibrosis using a digitally enabled cough monitor. 
Additionally, we will assess the feasibility of hybrid study design, 
utilizing cough monitoring and remote video-assisted home spi[INVESTIGATOR_038]. 
Study endpoints Primary Endpoint: Cough count per hour (CC/hr) measured over a 24-hour period at baseline visit, Week 4(V4), Week 8(V5), Week 12 (V6).
Secondary Endpoints: 
∀Change from baseline in CC/hr at Week 4, Week 8, Week 12
∀FVC (mL) at baseline
∀FVC (mL) at Week 12
∀Change from baseline in FVC (mL) at Week 12
∀Feasibility of remote cough data capture (defined as % of 
analysable data per 24-hour recording)
∀Feasibility of hybrid study design (successful completion of all 
elements of remote visit)
Study design Low intervention, 12-week pi[INVESTIGATOR_799], utilizing a digitally enabled cough monitor and hybrid study design, in subjects with IPF or Non IPF pulmonary fibrosis. 
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 4 of 71
Proprietary confidential information © [ADDRESS_313727]-03 (20.0) / Saved on: 20 Apr 2021FLOW CHART
Study Periods Screening* Baseline*
VisitRemote Study Visits EoS Visit
V i s i t 1 2 3456 7 / E o S  
Days - 1 wk 1 3 28 56 82 84
Time window for visits + 2 days ± 5 days ± 5 days - 2 days ± 5 days
Informed consent X
Review of in-/exclusion criteria X
 
Demographics X
Smoking Status/history  X
Medical history (Comorbidities) X
Pregnancy status (where available) X X
COVID-19 history (including vaccination status) X
Non IPF Pulmonary Fibrosis (including ILD
diagnosis category) or IPFX
Progressive Pulmonary Fibrosis Phenotype (Y/N) X
Concomitant therapy (including prescription 
medications for Pulmonary Fibrosis)XX XX
Historical Pulmonary Function Tests (FVC & 
DLCO)2X
Historical HRCT Pattern3(UIP, Probable UIP, 
Indeterminate for UIP, Inconsistent w/UIP)X
Physical examination X X
Vital signs4XX
SpO 2 XX
In-Office Spi[INVESTIGATOR_038]5XX
Distribute & provide instruction on cough monitor X
Distribute & provide instruction on home 
spi[INVESTIGATOR_258213] X7,9XX X7,9
Reporting of AEs/SAEs10& Unscheduled clinical 
visitsXX XX
Videoconference remote visit X X
24-hour cough monitor  
recording11 XX11X11X11
24-hour cough monitor data upload12XX X X
Remote Procedures Compliance Check 13
(Home spi[INVESTIGATOR_038], Videoconference remote visit (V4, V5), & Cough recordings)XXXX
Return of cough monitor & home spi[INVESTIGATOR_14007] X
Patient survey regarding use of cough monitor and 
home spi[INVESTIGATOR_258214] 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 6 of 71
Proprietary confidential information © [ADDRESS_313728]-03 (20.0) / Saved on: 20 Apr 2021TABLE OF CONTENTS
TITLE PAGE ..................................................................................................................... ......1
PROTOCOL SYNOPSIS ........................................................................................................ 2
FLOW CHART..................................................................................................................... ...4
TABLE OF CONTENTS ........................................................................................................ 6
ABBREVIATIONS AND DEFINITIONS............................................................................. 9
1. INTRODUCTION............................................................................................... 12
1.1 MEDICAL BACKGROUND............................................................................. 12
1.2 DEVICE PROFILE ............................................................................................ 13
1.3 RATIONALE FOR PERFORMING THE STUDY ........................................ 14
1.4 BENEFIT - RISK ASSESSMENT..................................................................... 14
1.4.1 Benefits................................................................................................................. 14
1.4.2 Risks ..................................................................................................................... 15
1.4.3 Discussion............................................................................................................. 15
2. STUDY OBJECTIVES AND ENDPOINTS..................................................... 16
2.1 MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS........ 16
2.1.1 Main objectives.................................................................................................... 16
2.1.2 Primary endpoint(s)............................................................................................ 16
2.1.3 Secondary endpoint(s) ........................................................................................ 16
3. DESCRIPTION OF DESIGN AND STUDY POPULATION ........................ 19
3.1 OVERALL STUDY DESIGN............................................................................ 19
3.2 DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUP(S) ...................................................................................... 19
3.3 SELECTION OF STUDY POPULATION....................................................... 20
3.3.1 Main diagnosis for study entry .......................................................................... 20
3.3.2 Inclusion criteria ................................................................................................. 20
3.3.3 Exclusion criteria ................................................................................................ 20
3.3.4 Discontinuation of patients from assessments.................................................. 21
[IP_ADDRESS] Withdrawal of consent to participation................................................................. 21
[IP_ADDRESS] Discontinuation of the study by [CONTACT_258243] ......................................... 22
4. TREATMENTS................................................................................................... 23
4.1 INVESTIGATIONAL INTERVENTION ........................................................ 23
4.1.1 Method of assigning patients to intervention group ........................................ 23
4.1.2 Storage conditions............................................................................................... 23
4.1.3 Device accountability .......................................................................................... 23
4.2 OTHER TREATMENTS, EMERGENCY PROCEDURES, 
RESTRICTIONS ................................................................................................ 24
4.2.1 Other treatments and emergency procedures .................................................. 24
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 7 of 71
Proprietary confidential information © [ADDRESS_313729]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE].2.2 Restrictions .......................................................................................................... 24
[IP_ADDRESS] Restrictions regarding concomitant treatment ...................................................... 24
[IP_ADDRESS] Restrictions on lifestyle......................................................................................... 24
[IP_ADDRESS] Contraception requirements .................................................................................. 24
4.3 DEVICE USE COMPLIANCE.......................................................................... 24
5. ASSESSMENTS.................................................................................................. 25
5.1 ASSESSMENT OF EFFICACY........................................................................ 25
5.2 ASSESSMENT OF SAFETY............................................................................. 28
5.2.1 Physical examination .......................................................................................... 28
5.2.2 Vital signs............................................................................................................. 29
5.2.3 Safety laboratory parameters ............................................................................ 29
5.2.4 Electrocardiogram .............................................................................................. 29
5.2.5 Other safety parameters..................................................................................... 29
5.2.6 Assessment of adverse events............................................................................. 29
[IP_ADDRESS] Definitions of AEs ................................................................................................ 29
[IP_ADDRESS] Adverse event collection and reporting ................................................................ 30
5.5 OTHER ASSESSMENTS................................................................................... 31
5.6 APPROPRIATENESS OF MEASUREMENTS .............................................. 31
6. INVESTIGATIONAL PLAN............................................................................. 33
6.1 VISIT SCHEDULE............................................................................................. 33
6.2 DETAILS OF STUDY PROCEDURES AT SELECTED VISITS ................ 36
6.2.1 Screening and run-in period(s) .......................................................................... 36
6.2.2 Intervention period ............................................................................................. 37
6.2.3 Study completion................................................................................................. 37
7. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE
............................................................................................................................... 38
7.1 NULL AND ALTERNATIVE HYPOTHESES ............................................... 38
7.2 PLANNED ANALYSES..................................................................................... 38
7.2.1 General considerations ....................................................................................... 38
7.2.2 Handling of Intercurrent Events ....................................................................... 38
7.2.3 Primary objective analyses................................................................................. 38
[IP_ADDRESS] Supplementary Analyses....................................................................................... 39
7.2.4 Secondary objective analyses ............................................................................. 40
7.2.6 Safety analyses..................................................................................................... 41
7.2.8 Interim Analyses ................................................................................................. 42
7.3 HANDLING OF MISSING DATA ................................................................... 42
7.4 RANDOMIZATION........................................................................................... 42
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 9 of 71
Proprietary confidential information © [ADDRESS_313730]-03 (20.0) / Saved on: 20 Apr 2021ABBREVIATIONS AND DEFINITIONS
(e)COA (electronic) Clinical Outcome Assessment
ACE Angiotensin-Converting Enzyme
AE Adverse Event
AESI Adverse Event of Special Interest
ALAT Asociación Latinoamericana de TóraxALCOA Attributable, Legible, Contemporaneous, Original, Accurate 
ALT Alanine Aminotransferase
AST Aspartate Aminotransferase
ATS American Thoracic Society
AUC Area under the Curve
BI Boehringer Ingelheim
C3M Fragment of type III collagen released by [CONTACT_258244]6M Fragment of type VIa1 collagen released by [CONTACT_258245]-2
CA Competent Authority
CA-125 (19.9) Cancer antigen-125 (19.9)
CBO Clinical Biosample Operations
CCI Commercially Confidential InformationCDP Clinical development plan
CES Cough Evaluable Set 
CI Confidence Interval
CRA Clinical Research Associate
CRF Case Report Form, paper or electronic (sometimes referred to as “eCRF”)
CRO Contract Research Organisation
CT Leader Clinical Trial LeaderCT Manager Clinical Trial Manager
CTCAE Common Terminology Criteria for Adverse Events
CTgov ClinicalTrials.gov
CTP Clinical Trial Protocol
CTR Clinical Study ReportDBL Database Lock
DLCO Diffusing Capacity of the Lungs for Carbon Monoxide
EC Ethics Committee
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 10 of 71
Proprietary confidential information © [ADDRESS_313731]-03 (20.0) / Saved on: 20 Apr 2021ECD Early Clinical Development
eCRF Electronic Case Report Form
eDC Electronic Data CaptureEoS End of Study (corresponds with End of Trial)
ePRO Electronic Patient Reported Outcome
ERS European Respi[INVESTIGATOR_258215]1 Forced expi[INVESTIGATOR_258216]-upFVC Forced Vital Capacity 
GCP Good Clinical Practice
GERD Gastroesophageal Reflux Disease 
GPV Global Pharmacovigilance
GRL Global Regulatory LeadHA Health Authority
HRCT High Resolution Computed Tomography
ICAM-[ADDRESS_313732] Infection
MMP-7 Matrix metalloproteinase 7
PF Pulmonary Fibrosis
 
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 11 of 71
Proprietary confidential information © [ADDRESS_313733]-03 (20.0) / Saved on: [ADDRESS_313734]
TMCP Translational Medicine & Clinical Pharmacology
TMF Trial Master File
UIP Usual Interstitial Pneumonitis
URI Upper Respi[INVESTIGATOR_258217] 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 15 of 71
Proprietary confidential information © [ADDRESS_313735]-03 (20.0) / Saved on: [ADDRESS_313736] wall is possible, though not anticipated, and if present would not be expected to be severe. Continuous audio recordings may raise concern for privacy breaches and/or inadvertent recording of conversations. The  biosensor data is fully encrypted on device and in transit to prevent unauthorized access to health information.  does not contain an open-air microphone and is not designed to acquire speech or other sounds from a patient's mouth. It is intended to acquire sounds of the lungs and airways including cough sounds, wheeze sounds and normal breath sounds. The file is reversed to avoid discernible speech (if incidentally acquired) being interpretable during a QA/QC session in addition to a speech filter being applied to the raw transmission data to remove speech signatures from review. Files are broken up into short <[ADDRESS_313737] of data privacy breaches. In all, we believe the interventions in this study are non-invasive, nonintrusive, and likely to offer more benefit than risk to patients who choose to participate. 
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 16 of 71
Proprietary confidential information © [ADDRESS_313738]-03 (20.0) / Saved on: [ADDRESS_313739] measures of cough intensity and the association between objective cough measures and lung physiology and various patient-reported outcome measures in a patient cohort with Non IPF forms of pulmonary fibrosis and IPF. We will perform these assessments with a digitally enabled cough monitor  and video assisted remote spi[INVESTIGATOR_258218].
2.1 MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS
2.1.1 Main objectives
The primary objective of this study is to objectively describe cough frequency, utilizing four 
24-hour cough recordings over 12 weeks in a cohort of subjects with Non IPF Pulmonary Fibrosis or IPF using the  cough monitor.
The secondary objectives for this study are: 
∀Assess the relationship between objective cough frequency and FVC (mL)
∀Assess feasibility of patient performed remote cough data upload
∀Assess feasibility of hybrid study design (% successful completion of remote visits) 
2.1.2 Primary endpoint(s)
Primary Endpoints: Cough count per hour (CC/hr) measured over a 24-hour period at 
baseline visit, Week 4(V4), Week 8(V5), Week 12 (V6).
2.1.3 Secondary endpoint(s)
Secondary endpoints include: 
∀Change from baseline in CC/hr at Week 4, Week 8, Week 12.
∀FVC (mL) at baseline
∀FVC (mL) at Week 12
∀Change from baseline in FVC (mL) at Week 12
∀Feasibility of remote cough data capture (defined as % of analysable data per 24-hour 
recording)
∀Feasibility of hybrid study design (successful completion of all elements of remote visit)
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 17 of 71
Proprietary confidential information © [ADDRESS_313740]-03 (20.0) / Saved on: 20 Apr 2021
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 18 of 71
Proprietary confidential information © [ADDRESS_313741]-03 (20.0) / Saved on: 20 Apr 2021
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 20 of 71
Proprietary confidential information © [ADDRESS_313742]-03 (20.0) / Saved on: 20 Apr 2021pi[INVESTIGATOR_258219]. 
3.3 SELECTION OF STUDY POPULATION
The study population will include subjects (aged 18 and above) with Non IPF Pulmonary 
Fibrosis (defined as > 10% fibrosis on high resolution Chest CT as per principal investigator 
[INVESTIGATOR_13699]) or IPF who are residing in one of the target countries and follow the routine clinical practice of the participating sites. We will target enrolment of 25 subjects with Non IPF Pulmonary Fibrosis and 25 with IPF. Screening of patients for this study is competitive, i.e. screening for the study will stop at all sites at the same time once a sufficient number of patients has been screened. Investigators will be notified about screening completion and will then not be allowed to screen additional patients for this study. Patients already in screening at this time will be allowed to continue to enrollment if eligible. 
A log of all patients enrolled into the study (i.e. who have signed informed consent) will be 
maintained in the Investigator Site File (ISF) irrespective of whether they chose to complete the study or not. 
3.3.1 Main diagnosis for study entry
The study population will include subjects (aged 18 and above) with Non IPF Pulmonary 
Fibrosis or IPF, who are residing in one of the target countries. The study population will be enriched (70% of study population) for persons with clinically significant cough at the Screening Visit, defined as having  
3.3.2 Inclusion criteria
Subjects fulfilling all the following inclusion criteria will be eligible for participation in the 
study: 
1. Provision of signed informed consent in writing prior to study data collection2. Subject aged [ADDRESS_313743] diagnosed with Non IPF Pulmonary Fibrosis (>10% fibrosis on HRCT by 
[CONTACT_22660] [INVESTIGATOR_13699]) or IPF as per ATS/ERS/JRS/ALAT Guidelines[P22-[ZIP_CODE] ] within the past 12 months
4. FVC > 40% predicted at baseline visit
5. Life expectancy > 6 months (per assessment of treating physician)
3.3.3 Exclusion criteria
Subjects fulfilling any of the following exclusion criteria will not be eligible for participation 
in the study: 
1. Current smokers
2. URI or LRTI (including COVID-19 infection) within 4 weeks of screening visit3. Airflow obstruction (FEV1/FVC < 70%) at baseline or known history of significant 
spi[INVESTIGATOR_258220]
4. Cough due to etiology other than ILD (e.g., allergic rhinitis, GERD)
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 21 of 71
Proprietary confidential information © [ADDRESS_313744]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE]. Other respi[INVESTIGATOR_258221], but not limited to, a current diagnosis of any 
obstructive disease including chronic obstructive pulmonary disease (COPD) and asthma, active tuberculosis, lung cancer in treatment or in medical history, sleep apnea, known alpha-1 antitrypsin deficiency, cor pulmonale, clinically significant pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary diseases.
6. Initiation or change in dose or type of anti-tussive medication, angiotensin-converting 
enzyme (ACE) inhibitors, opi[INVESTIGATOR_858], and systemic or inhaled (excluding intranasal)corticosteroids in the [ADDRESS_313745] participating in a clinical study of a systemic or inhaled drug at the time of 
enrollment 
9. Visual, cognitive, motor or health impairment that, as judged by [CONTACT_093], may 
cause concern regarding the subjects’ ability to complete study assessments 
10. Subject not being fluent and literate in one of the main languages of the country 
3.3.4 Discontinuation of patients from assessments
Patients may discontinue study participation or withdraw consent to study participation at any 
time (“withdrawal of consent”). If the patients agree, they should stay in the study. Even if continuing to wear the cough monitor is not possible, they should attend further study visits to collect important study data.
An individual patient will discontinue the study if: 
∀The patient has repeatedly shown to be non-compliant with important study procedures 
and, in the opi[INVESTIGATOR_15566], the investigator and contracting entity representative, is not willing or able to adhere to the study requirements in the future.
∀The patient can no longer perform the study procedures for medical reasons
Measures to control the withdrawal rate include careful patient selection, appropriate 
explanation of the study requirements and procedures prior to study enrolment, as well as theexplanation of the consequences of withdrawal. 
The decision to discontinue or withdraw consent to study participation and the reason must be 
documented in the patient files and CRF.
[IP_ADDRESS] Withdrawal of consent to participationPatients may withdraw their consent to participation at any time without the need to justify 
the decision.
If a patient wants to withdraw consent, the investigator should be involved in the discussion 
with the patient and the options for continued follow-up after discontinuation of remote monitoring and other study procedures.
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 22 of 71
Proprietary confidential information © [ADDRESS_313746]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE].3.4.2 Discontinuation of the study by [CONTACT_258246] a particular 
study site at any time for the following reasons:
1. Failure to meet expected enrolment goals overall or at a particular study site.
2. New safety information invalidating the earlier positive benefit-risk-assessment, 
please see Section 1.[ADDRESS_313747] of the study.
Further assessment and follow up of patients affected will occur as described in Section 
[IP_ADDRESS] .
The investigator / the study site will be reimbursed for reasonable expenses incurred in case 
of study termination (except in case of the third reason).
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 23 of 71
Proprietary confidential information © [ADDRESS_313748]-03 (20.0) / Saved on: [ADDRESS_313749] will be administered. Please see Section 1.2 .  
4.1.1 Method of assigning patients to intervention group
All enrolled subjects will receive the intervention of utilizing a wearable cough monitoring 
device with an accompanying mobile application (App) for data. All enrolled subjects will also receive a home spi[INVESTIGATOR_258222] (for the study duration). 
4.1.[ADDRESS_313750] environmental conditions (-25°C to 50°C, 15% to 93% RH ± 3%, 700hPa to 1,070hPa).  When not in use and between measurements the patient can store the wearable device on the charger.  The charger was designed to fit within a small footprint on a table or desktop.
4.1.3 Device accountability
The investigator or designee will receive the  system kit, as delivered by [CONTACT_258247]:
∀Approval of the study protocol by [CONTACT_1201] / ethics committee and/or HA approval
∀Availability of a signed and dated study protocol contract between the contracting entity
contracting entity or delegate and the investigational site,
∀Approval / notification of the regulatory authority, e.g. competent authority,
∀Availability of the curriculum vitae of the Principal Investigator,
∀Availability of a signed and dated study protocol,
∀Availability of the proof of a medical license for the Principal Investigator,
∀Availability of FDA Form 1572 (if applicable).
Investigational devices are not allowed to be used outside the context of this protocol. They 
must not be forwarded to other investigators or clinics. Patients should be instructed to return unused devices and/or devices upon study completion. 
The investigator or designee must maintain records of the product’s delivery to the study site, 
the inventory at the site, the use by [CONTACT_6904], and the return to the contracting entity of unused products. 
These records will include dates, quantities, batch / serial numbers, expi[INVESTIGATOR_4061] (‘use- by’) dates, 
and the unique code numbers assigned to the study patients. The investigator or designee will maintain records that document adequately that the patients were provided the device(s) specified by [CONTACT_4690]. At the time of return to the contracting entity the investigator
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 24 of 71
Proprietary confidential information © [ADDRESS_313751]-03 (20.0) / Saved on: [ADDRESS_313752] been returned by [CONTACT_258248]’s possession.
4.2 OTHER TREATMENTS, EMERGENCY PROCEDURES, 
RESTRICTIONS
4.2.1 Other treatments and emergency procedures
There are no special emergency procedures to be followed. 
4.2.2 Restrictions
[IP_ADDRESS] Restrictions regarding concomitant treatment
As per the Exclusion criteria (3.3.3), persons who have had initiation of a change in dose of 
ACE-I therapy, inhaled steroid therapy (excluding intranasal), systemic corticosteroid, anti-tussive therapy (including over the counter medications) or opi[INVESTIGATOR_258223] [ADDRESS_313753] notify the contracting entitywithin 72 hours.
[IP_ADDRESS] Restrictions on lifestylePatients can perform most forms of exercise, typi[INVESTIGATOR_258224]. Full submersion into water (e.g. swimming, hot tub use or baths) is not advised as it may lead to device malfunction and compromise any further data collection. 
[IP_ADDRESS] Contraception requirementsNo contraception requirements are necessitated by [CONTACT_258249]. 
4.3 DEVICE USE COMPLIANCE
Compliance with cough recordings will be assessed based on patient adherence to cough 
monitoring (defined as % of time over th e 24-hour recording period that the patient is 
wearing the cough monitor) and remote cough data capture (defined as % of analyzable dataper 24-hour recording).
Site staff will receive notification via email each time a patient completes a cough count 
recording with successful data upload. If the site does not receives this type of notification, the site should contact [CONTACT_258250] 24 hour cough recording and upload.  
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 26 of 71
Proprietary confidential information © [ADDRESS_313754]-03 (20.0) / Saved on: [ADDRESS_313755] FVC obtained on any of three blows meeting the 2019 ATS/ERS criteria (with a maximum of eight attempts). Predicted normal values will be calculated according to GLI (Global Lung Initiative). Efforts should be made to schedule the spi[INVESTIGATOR_258225], at least within the same half-day (morning vs afternoon), with reference to baseline measurement (Visit 2). On days of study visits, patients should be encouraged to refrain from vigorous activity within 1 hour of pulmonary function testing. If treated with bronchodilators, washout should be advised before spi[INVESTIGATOR_258226]. If treated with bronchodilators, wash-out of 24 hours for long acting and 8 hours for short acting bronchodilators should be observed before spi[INVESTIGATOR_258227]. Spi[INVESTIGATOR_258228]. To ensure the quality of the spi[INVESTIGATOR_258229], a manual overread will be performed by [CONTACT_96945][INVESTIGATOR_258230]. Further instructions regarding FVC measurements will be provided in the ISF. 
Video supervised home spi[INVESTIGATOR_258231]. Patients will receive 
instruction on the video supervised home spi[INVESTIGATOR_258232] (V2). The first “home spi[INVESTIGATOR_038]” measure will be performed at home two days following the baseline study visit (with study coordinator instruction and video assisted supervision). Patients will also perform video supervised home spi[INVESTIGATOR_258233] 4, 5, and 6. For the video-assisted home spi[INVESTIGATOR_038], patients will use a handheld spi[INVESTIGATOR_258234] a mobile phone with the installed App provided by [CONTACT_3725]. These home spi[INVESTIGATOR_258235] 2 and Visit 7(Week 12).
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 27 of 71
Proprietary confidential information © [ADDRESS_313756]-03 (20.0) / Saved on: 20 Apr 2021
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 28 of 71
Proprietary confidential information © [ADDRESS_313757]-03 (20.0) / Saved on: [ADDRESS_313758] be included in the source documents. 
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 29 of 71
Proprietary confidential information © [ADDRESS_313759]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE].2.2 Vital signs
Vital signs will be evaluated at Visit 2 and 7, as specified in the Flow Chart , prior to blood 
sampling. This includes systolic and diastolic blood pressure and pulse rate (electronically or 
by [CONTACT_15620] 1 minute) in a seated position after [ADDRESS_313760] be included in the source documents. 
5.2.3 Safety laboratory parameters
Safety laboratory parameters will not be performed. 
5.2.4 Electrocardiogram
ECGs will not be routinely performed. 
5.2.5 Other safety parameters
Should the patient demonstrate a > 10% absolute or relative drop in forced vital capacity 
(FVC) during on-site or home spi[INVESTIGATOR_038], the site principal investigator [INVESTIGATOR_258236]. 
5.2.6 Assessment of adverse events
[IP_ADDRESS] Definitions of AEs 
[IP_ADDRESS].[ADDRESS_313761] a causal relationship with this Intervention.
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medical intervention, whether considered related or not.
The following should be recorded as an AE in the CRF (if applicable):
∀AEs related to study procedures
∀AEs or SAEs that fufill the following criteria: 
oEvents leading to lung transplantation
oCOVID-19 Infection 
oEvents leading to death  
[IP_ADDRESS].2 Serious adverse eventA serious adverse event (SAE), is defined as any AE, which fulfils at least one of the 
following criteria:
∀results in death
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 30 of 71
Proprietary confidential information © [ADDRESS_313762]-03 (20.0) / Saved on: 20 Apr 2021∀is life-threatening, which refers to an event in which the patient was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death if more severe, 
∀requires inpatient hospi[INVESTIGATOR_15574] 
∀results in persistent or significant disability or incapacity, 
∀is a congenital anomaly / birth defect, 
∀is deemed serious for any other reason if it is an important medical event when based on 
appropriate medical judgement which may jeopardise the patient and may require medial or surgical intervention to prevent one of the other outcomes listed in the abovedefinitions. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_23236]. 
SAEs related to study procedures, or as defined in Section [IP_ADDRESS].1 , should be recorded in 
the CRF.
No SAE reporting to drug safety will occur, hence no SAE reconciliation required.
[IP_ADDRESS].3 AEs considered “Always Serious”Not applicable5.[IP_ADDRESS] Adverse Events of Special InterestNot applicable5.2.6.2 Adverse event collection and reporting5.[IP_ADDRESS] AE CollectionThe investigator shall maintain and keep detailed records of all AEs in the patient files.
The following must be collected and documented on the appropriate CRF(s) by [CONTACT_1275]:
∀From signing the informed consent onwards until the individual patient’s end of study (= 
the End of Study (EoS) visit): all AEs (serious and non-serious) as defined in Section [IP_ADDRESS].1 .
[IP_ADDRESS].2 AE reporting to the contracting entity and timelines
Not applicable5.[IP_ADDRESS] Exemptions to SAE reportingNot applicable 
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 31 of 71
Proprietary confidential information © [ADDRESS_313763]-03 (20.0) / Saved on: [ADDRESS_313764] and routine measure utilized in studies of 
anti-tussive therapy. In the current pi[INVESTIGATOR_2268], we will also measure, “cough intensity”, which is not routinely captured by [CONTACT_258251]. As such, it is not a measure that is routinely included in published literature to date. In the current study, we will assess cough
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 32 of 71
Proprietary confidential information © [ADDRESS_313765]-03 (20.0) / Saved on: 20 Apr 2021intensity, measured as an analysis of a combination of the following parameters: cough duration (% of minute recordings taken up by [CONTACT_86063]), variability of  minute-to-minute cough%/minute, time interval of coughs (msec) on x axis, amplitude of cough on y-axis, AUC of cough per cough or cough spasm, and within cough power (measured by [CONTACT_68458] -clear, blue, yellow, red; worst color present and change in color over time).
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 37 of 71
Proprietary confidential information © [ADDRESS_313766]-03 (20.0) / Saved on: 20 Apr 2021∀Will be collected at the Screening/Baseline visit
6.2.[ADDRESS_313767] cough recordings over a period of 12 
weeks from study entry until the End of Study visit. 
6.2.3 Study completion
Patients will complete study procedures at Visit 7/EOS and return the cough monitor, 
provisioned mobile phone and home spi[INVESTIGATOR_258237]. Completion of study procedures and return of the provisioned equipment at this visit will constitute study completion. 
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 38 of 71
Proprietary confidential information © [ADDRESS_313768]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE]. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
7.1 NULL AND ALTERNATIVE HYPOTHESES
This is an exploratory study with no treatment intervention aiming to assess the use of a new 
generation of cough monitoring device and describe cough frequency over 12 weeks. No confirmatory testing is performed and hence no null and alternative hypotheses are defined.  A justification of the sample size is provided in Section 7.4 .
7.2 PLANNED ANALYSES
7.2.1 General considerations
Cough count/hr will be log transformed for analysis.  Standard statistical parameters (number 
of non-missing values, mean, standard deviation (SD), median, quartiles, minimum andmaximum) or frequency tables will be calculated where appropriate. All individual data will be listed.
Patient analysis sets:
Entered Set (ES): those patients who were entered into the study.
Additional patient analysis sets may be defined in the SAP.
7.2.2 Handling of Intercurrent Events
This section is not applicable as there is no comparison of interventions.
7.2.3 Primary objective analyses
The cough count (CC) frequency, measured over 4 24-hour recordings in 12 weeks will be 
analysed as CC/hour and will be log-transformed for data summaries.  On each day for which cough monitoring is completed, the log-transformed cough count is calculated as:
Log-transformed cough count = logNumber of coughs
Length of recorded time (hours)
Cough count for each visit will be reported descriptively.  Summary statistics will be 
tabulated on original scale of CC/hr as well as the geometric mean and 95% confidence intervals after back-transforming the summarized log transformed data.   
  Summary measurements and individual values 
of CC/hr over time will also be presented graphically.
Additional details will be included in the SAP.
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 39 of 71
Proprietary confidential information © [ADDRESS_313769]-03 (20.0) / Saved on: 20 Apr 2021The primary endpoints will be summarized in the same fashion as described above by [CONTACT_258252].
[IP_ADDRESS] Supplementary AnalysesNot applicable
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 40 of 71
Proprietary confidential information © [ADDRESS_313770]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE].2.4 Secondary objective analyses
Secondary endpoints will be summarized descriptively by [CONTACT_765].  
Change from baseline in CC/hr at Week 4, Week 8, and Week 12 will be summarized in 
terms of absolute changes in CC/hr and in terms of geometric mean ratios.  Model based estimates for changes from baseline at Week 12, for example least squares means adjusted for baseline CC/hr or other covariates, may be calculated.
Standard descriptive statistical parameters will be tabulated for all other secondary endpoints.To assess the relationship between objective cough frequency and FVC (mL), correlations
(spearman and Pearson) will be calculated between the following variables:
∀Baseline CC/hr (log-transformed) and Baseline FVC (mL)
∀Baseline CC/hr (log-transformed) and FVC (mL) at Week 12
∀Baseline CC/hr (log-transformed) and change from baseline FVC (mL) at Week 12
∀CC/hr at Week 12 (log-transformed) and FVC (mL) at Week 12
∀Change in CC/hr at Week 12 (calculated from log-transformed values) and change
from baseline in FVC (mL) at Week 12
Graphical presentations of the secondary endpoints and correlations may also be produced.  
Further details will be included in the SAP.
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 41 of 71
Proprietary confidential information © [ADDRESS_313771]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE].2.6 Safety analyses
Adverse events will be coded using the Medical Dictionary for Drug Regulatory Activities
(MedDRA). Standard BI summary tables and listings will be produced.All enrolled patients will be included in the safety analysis. In general, safety analyses will be descriptive in nature and will be based on BI standards. No hypothesis testing is planned.
Frequency and severity of adverse events related to the study procedure will be tabulated by 
[CONTACT_258253] (MedDRA) at database lock.
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 42 of 71
Proprietary confidential information © [ADDRESS_313772]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE].2.8 Interim Analyses
Interim analyses will be performed as needed to inform subsequent studies. 
7.3 HANDLING OF MISSING DATA
Imputation of missing data will not be done.  Unless otherwise noted, analysis will be 
conducted using all patients with the endpoint available.
Missing or incomplete AE dates will be imputed according to BI standards.
7.4 RANDOMIZATION
but to gain experience using the  device in a real-world setting, therefore no 
randomization is needed for this single group study.
7.5 DETERMINATION OF SAMPLE SIZE
[P22-[ZIP_CODE] ] was a phase 2a study which investigated the effect of inhaled RVT-1601 
(cromolyn sodium) on 24-hour average cough counts in patients with IPF.  97 patients were 
randomized to four arms (RVT-1601 10mg, 40mg, 80mg, or placebo for 12 weeks).  The baseline measurements of the mean 24-hour cough count were 38.0 ± 26.6 (RVT-1601 10mg; n=27); 36.8 ± 21.7 (RVT-1601 40mg arm; n=22); 35.7 ± 17.8 (RVT-1601 80mg arm; n=23); 34.3 ± 19.6 (Placebo; n=25).
Assuming we observe similar standard deviations for cough count as the SCENIC trial, the 
table below reports the 95% confidence interval range we expect for the 24-hour cough count assuming a sample size of 50 patients that are normally distributed.  For example, when the sample size is 50, a two-sided 95% confidence interval for a mean will extend 7.[ADDRESS_313773] deviation is known to be 27 and the confidence interval is based on the large sample z-statistic.
Table 7.5: 1 Confidence Interval ranges based on N=[ADDRESS_313774] Deviation 19 21 23 25 27
95% CI Range* ±5.266 ±5.821 ±6.375 ±6.930 ±7.484
*CI Range calculated using the NQuery 8, Version [IP_ADDRESS] program for “Confidence Interval for One Mean using 
Normal Distribution”
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 43 of 71
Proprietary confidential information © [ADDRESS_313775]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE]. INFORMED CONSENT, STUDY RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND
ADMINISTRATIVE STRUCTURE
The study will be carried out in accordance with the Medical Devices Directive (93/42/EEC) 
and the harmonised standards for Medical Devices (ISO [ZIP_CODE], current version).
The study will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the ICH Harmonized Guideline for Good Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the EU directive 2001/20/EC / EU regulation 536/2014. Investigators and site staff must adhere to these principles. Deviation from the protocol, the principles of ICH GCP or applicable regulations as will be treated as “protocol deviation”.Standard medical care (prophylactic, diagnostic and therapeutic procedures) remains the responsibility of the treating physician of the patient.
The investigator will inform the contracting entity or delegate immediately of any urgent 
safety measures taken to protect the study patients against any immediate hazard, as well as of any serious breaches of the protocol or of ICH GCP.
The Boehringer Ingelheim transparency and publication policy can be found on the following 
web page: trials.boehringer-ingelheim.com. The rights of the investigator and of the 
contracting entity with regard to publication of the results of this study are described in the investigator contract. As a rule, no study results should be published prior to finalisation of the Study Report.
The certificate of insurance cover is made available to the investigator and the patients and is
stored in the ISF.
8.[ADDRESS_313776] (IRB / Independent Ethics Committee (IEC and competent authority (CA) according to national and international regulations. The same applies for the implementation of changes introduced by [CONTACT_15635].Prior to patient participation in the study, written informed consent must be obtained from each patient (or the patient’s legally accepted representative) according to ICH-GCP and to the regulatory and legal requirements of the participating country. Each signature [CONTACT_23362] [CONTACT_23343]-information form retained by [CONTACT_258254]. A signed copy of the informed consent and any additional patient information must be given to each patient or the patient’s legally accepted representative.The patient must be given sufficient time to consider participation in the study. The investigator or delegate obtains written consent of the patient’s own free will with the informed consent form after confirming that the patient understands the contents. The investigator or  delegate must sign (or place a seal on) and date the informed consent form. If a study collaborator has given a supplementary explanation, the study collaborator also 
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 44 of 71
Proprietary confidential information © [ADDRESS_313777]-03 (20.0) / Saved on: 20 Apr 2021signs (or places a seal on) and dates the informed consent.Re-consenting may become necessary when new relevant information becomes available and should be conducted according to the contracting entity’s instructions.The consent and re-consenting process should be properly documented in the source documentation.
8.[ADDRESS_313778], studydesign or monitoring approaches. A quality assurance audit / inspection of this study may be conducted by [CONTACT_258243], contracting entity’s designees, or by [CONTACT_1744] / IEC or by [CONTACT_12721]. The quality assurance auditor will have access to all medical records, the investigator’s study-related files and correspondence, and the informed consent documentation of this study.
8.3 RECORDS
CRFs for individual patients will be provided by [CONTACT_258243].
8.3.1 Source documents
In accordance with regulatory requirements, the investigator should prepare and maintain 
adequate and accurate source documents and study records that include all observations and other data pertinent to the investigation on each study patient. Source data as well as reported data should follow the “ALCOA principles” and be attributable, legible, contemporaneous, 
original and accurate. Changes to the data should be traceable (audit trail).
Data reported on the CRF must be consistent with the source data or the discrepancies must be explained.The current medical history of the patient may not be sufficient to confirm eligibility for the study and the investigator may need to request previous medical histories and evidence of any diagnostic tests. In this case, the investigator must make at least one documented attempt to retrieve previous medical records. If this fails, a verbal history from the patient, documented in their medical records, would be acceptable.Before sending or uploading those copi[INVESTIGATOR_014], the investigator must ensure that all patientidentifiers (e.g. patient’s name, initials, address, phone number, social security number) have properly been removed or redacted from any copy of the patients’ source documents.If the patient is not compliant with the protocol, any corrective action e.g. re-training must be documented in the patient file.For the CRF, data must be derived from source documents, for example:
∀Patient identification: gender, year of birth (in accordance with local laws and 
regulations)
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 45 of 71
Proprietary confidential information © [ADDRESS_313779]-03 (20.0) / Saved on: 20 Apr 2021∀Patient participation in the study (substance, study number, patient number, date patient
was informed)
∀Dates of patient’s visits.
∀Medical history (including study indication and concomitant diseases, if applicable)
∀Medication history
∀Adverse events and outcome events (onset date (mandatory), and end date (if available))
∀Serious adverse events (onset date (mandatory), and end date (if available))
∀Concomitant therapy (start date, changes)
∀Originals or copi[INVESTIGATOR_23242], with proper 
documented medical evaluation (in validated electronic format, if available)
∀Completion of patient’s participation in the study (end date; in case of premature 
discontinuation document the reason for it).
∀Prior to enrolment of a patient to this study, there must be documented evidence in the 
source data (e.g. medical records) that the study participant meets all inclusion criteria and does not meet any exclusion criteria. The absence of records (either medical records, verbal documented feedback of the patient or testing conducted specific for a protocol) to support inclusion / exclusion criteria does not make the patient eligible for the study.
8.3.[ADDRESS_313780] access to source data and documents
The investigator / institution will allow site study-related monitoring, audits, IRB / IEC 
review and regulatory inspections. Direct access must be provided to the CRF and all source documents / data, including progress notes, copi[INVESTIGATOR_15587], which must always be available for review by [CONTACT_2689], auditor and regulatory inspector (e.g. FDA). They may review all CRFs and informed consents. The accuracy of the data will be verified by [CONTACT_35977] 8.3.1 .T h e  
contracting entity or delegate will also monitor compliance with the protocol and GCP.
8.3.3 Storage period of records
Study site(s):
The study site(s) must retain the source and essential documents (including ISF) according to 
contract or the local requirements valid at the time of the end of the study (whatever is longer).Contracting entity:
The contracting entity must retain the essential documents according to the contracting entity’s SOPs.
8.4 EXPEDITED REPORTING OF ADVERSE EVENTS
BI is responsible to fulfil their legal and regulatory reporting obligation in accordance with
regulatory requirements. 
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 46 of 71
Proprietary confidential information © [ADDRESS_313781]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE].5 STATEMENT OF CONFIDENTIALITY AND PATIENT PRIVACY
Data protection and data security measures are implemented for the collection, storage and 
processing of patient data in accordance with the principles 7 and 12 of the WHO GCP handbook. To ensure confidentiality of records and personal data, only pseudonymised data will be transferred to the contracting entity by [CONTACT_2329] a patient identification number instead of the patient’s name. The code is only available at the site and must not be forwarded to the contracting entity. In case patient’s records will be forwarded e.g. for SAE processing or adjudication committees, personal data that can identify the patient will be redacted by [CONTACT_258255]. Access to the patient files and clinical data is strictly limited: personalised treatment data may be given to the patient’s personal physician or to other appropriate medical personnel responsible for the patient’s welfare. Data generated at the site as a result of the study need to be available for inspection on request by [CONTACT_23351], the contracting entity’s representatives, by [CONTACT_1201] / IEC and the regulatory authorities.
A potential data security breach will be assessed regarding the implications for rights and 
privacy of the affected person(s). Immediate actions as well as corrective and preventive actions will be implemented. Respective regulatory authorities, IRBs / IECs and patients will be informed as appropriate.
8.[ADDRESS_313782] patient in the whole 
study (“Last Patient Completed”). Early termination of the study is defined as the 
premature termination of the study due to any reason before the end of the study as specified in this protocol.Temporary halt of the study is defined as any unplanned interruption of the study by [CONTACT_258256].Suspension of the study is defined as an interruption of the study based on a Health 
Authority request.
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 47 of 71
Proprietary confidential information © [ADDRESS_313783]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE].7 ADMINISTRATIVE STRUCTURE OF THE STUDY
The study is sponsored by [CONTACT_23347] (BI).
A Coordinating Investigator [INVESTIGATOR_258238]. Tasks and responsibilities are defined in a contract. 
Relevant documentation on the participating (Principal) Investigators (e.g. their curricula 
vitae) will be filed in the ISF.
BI has appointed a Clinical Trial Leader responsible for coordinating all required activities, in 
order to 
- manage the study in accordance with applicable regulations and internal SOPs,- direct the study team in the preparation, conduct, and reporting of the study,- ensure appropriate training and information of Clinical Trial Managers (CT 
Managers), Clinical Research Associates (CRAs), and investigators of participating countries.
In the participating countries the study will be performed by [CONTACT_195913]-organisation (Operating Unit, OPU) in accordance with applicable regulations and BISOPs.
Data Management and Statistical Evaluation will be done by [CONTACT_15640].Tasks and functions assigned in order to organise, manage, and evaluate the study are defined 
according to BI SOPs. A list of responsible persons and relevant local information can be found in the ISF.A central laboratory service will be used in this study. Details will be provided in the Central Laboratory Manual, available in the ISF.
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 48 of 71
Proprietary confidential information © [ADDRESS_313784]-03 (20.0) / Saved on: 20 Apr [ZIP_CODE]. REFERENCES
9.1 PUBLISHED REFERENCES
P18-[ZIP_CODE] Van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell 
AM, Wijsenbeek MS. Cough in idiopathic pulmonary fibrosis. European Respi[INVESTIGATOR_258239]. 2016 Sep 1;25(141):278-86.
P22-[ZIP_CODE] Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, 
Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respi[INVESTIGATOR_50165]. 2022 May 1;205(9):e18-47.
P22-[ZIP_CODE] Martinez FJ, Wijsenbeek MS, Raghu G, Flaherty KR, Maher TM, Wuyts 
WA, Kreuter M, Kolb M, Chambers DC, Fogarty C, Mogulkoc N. Phase 2B study of inhaled RVT-1601 for chronic cough in idiopathic pulmonary fibrosis: a multicenter, randomized, placebo-controlled study (SCENIC trial). American journal of respi[INVESTIGATOR_4447]. 2022 May 1;205(9):1084-92. 
P22-[ZIP_CODE] Lee J, White E, Freiheit E, Scholand MB, Strek ME, Podolanczuk AJ, et al. 
Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: Data from the pulmonary fibrosis foundation patient registry. Chest. 2022.
R12-[ADDRESS_313785] H. Cough 
predicts prognosis in idiopathic pulmonary fibrosis. Respi[INVESTIGATOR_16921]. 2011;16(6):969-975.
R16-0722 Schwartz MI, King TE . Interstitial lung disease. 5th ed. People’s Medical 
Publishing House; 2011.
R20-2419 Graham BL, Steenbruggen I, Miller MR, et al., American Thoracic Society,
European Respi[INVESTIGATOR_3764]. Standardization of spi[INVESTIGATOR_038] 2019 update:an official American Thoracic Society and European Respi[INVESTIGATOR_258240]. Am J Respir Crit Care Med 2019;200(8):e70-e88.
R20-3543 Olson A, Hartmann N, Schlenker-Herceg R, Wallace L. Prevalence of 
progressive fibrosing interstitial lung disease. In: Rare ILD/DPLD. European Respi[INVESTIGATOR_3764]; 2018.
R22-2496 Araos J, Alegria L, Garcia P, Cruces P, Soto D, Erranz B et al. Near-Apneic 
Ventilation Decreases Lung Injury and Fibroproliferation in an Acute Respi[INVESTIGATOR_258241]. American Journal of Respi[INVESTIGATOR_50165]. 2019;199(5):603-612.
R22-2497 Froese AR, Shimbori C, Bellaye PS, Inman M, Obex S, Fatima S, Jenkins 
G, Gauldie J, Ask K, Kolb M. Stretch-induced activation of transforming growth factor- β1 in pulmonary fibrosis. American journal of respi[INVESTIGATOR_116880]. 2016 Jul 1;194(1):84-96. 
R22-2498 Man W, Kyroussis D, Fleming T, Chetta A, Harraf F, Mustfa N et al. 
Cough Gastric Pressure and Maximum Expi[INVESTIGATOR_258242]. American Journal of Respi[INVESTIGATOR_50165]. 2003;168(6):714-717.
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 49 of 71
Proprietary confidential information © [ADDRESS_313786]-03 (20.0) / Saved on: 20 Apr 2021R22-2499 Sharpey-Schafer E. Effects of coughing on intra-thoracic pressure, arterial 
pressure and peripheral blood flow. The Journal of Physiology. 1953;122(2):351-357.
R22-[ADDRESS_313787]. 2021;160(5):1774–82.
9.2 UNPUBLISHED REFERENCES
Not applicable
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 50 of 71
Proprietary confidential information © [ADDRESS_313788]-03 (20.0) / Saved on: 20 Apr 202110. APPENDICES
10.1 INSTRUCTIONS FOR USE
Patient will be provided with User Manuals for the study devices
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 52 of 71
Proprietary confidential information © [ADDRESS_313789]-03 (20.0) / Saved on: 20 Apr 2021
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 53 of 71
Proprietary confidential information © [ADDRESS_313790]-03 (20.0) / Saved on: 20 Apr 2021
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 58 of 71
Proprietary confidential information © [ADDRESS_313791]-03 (20.0) / Saved on: 20 Apr 2021
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 65 of 71
Proprietary confidential information © [ADDRESS_313792]-03 (20.0) / Saved on: 20 Apr 2021
Boehringer Ingelheim 16 Sep 2022
BI Study No.: 1490-0005c39406431-01 Protocol Page 71 of 71
Proprietary confidential information © [ADDRESS_313793]-03 (20.0) / Saved on: 20 Apr 202111. DESCRIPTION OF GLOBAL AMENDMENT(S)
This is the original protocol.
   
APPROVAL / SIGNATURE [CONTACT_23364]:  Technical Version Number:
Document Name: 
                                                                                                                  
[CONTACT_1641]: 
                                                                                                                   
Signatures (obtained electronically) 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
  
  
  
   
   
   F 
FOLQLFDOWULDOSURWRFROYHUVLRQ
$PXOWLFHQWHUORQJLWXGLQDOZHHNSLORWVWXG\WRHYDOXDWHFR XJKVHYHULW\DQGLWV
LPSDFWXWLOL]LQJDQH[WJHQHUDWLRQFRXJKPRQLWRULQSDUWLFLSD QWVZLWKLGLRSDWKLF
SXOPRQDU\ILEURVLV,3)RU1RQ,3)3XOPRQDU\)LEURVLV
$XWKRU7ULDO6WDWLVWLFLDQ 6HS&(67
$SSURYDO 6HS&(67
$SSURYDO&OLQLFDO3URJUDP 6HS&(67
9HULILFDWLRQ3DSHU6LJQDWXUH
&RPSOHWLRQ6HS&(67
Boehringer Ingelheim Page  2 of 2
Document Number: Technical Version Number :
(Continued) Signatures (obtained electronically) 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
   
   
   
   
   
   
      
   F 